Abstract
We conducted an open-label pilot clinical trial to evaluate the safety and efficacy of adding oral azathioprine to the treatment regimen of 15 multiple sclerosis patients breaking through monotherapy with interferon β-1b. There were no serious adverse events. Gastrointestinal side effects and leukopenia were the most common adverse events and limited dose escalation. There was a 65% reduction in the number of gadolinium-enhanced magnetic resonance imaging (MRI) lesions on combination therapy compared to the baseline values (P =0.003). A total WBC count less than 4800/mm3 was the best predictor of MRI response.
Original language | English (US) |
---|---|
Pages (from-to) | 169-174 |
Number of pages | 6 |
Journal | Multiple Sclerosis |
Volume | 11 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2005 |
Keywords
- 6-thioguanine
- Immunosuppression
- MRI
- Therapy
- Toxicity
ASJC Scopus subject areas
- Neurology
- Clinical Neurology